Welcome to our dedicated page for Steris Plc SEC filings (Ticker: STE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings for STERIS plc (NYSE: STE) provide detailed regulatory information about this Ireland-incorporated medical technology company, which focuses on products and services that support patient care with an emphasis on infection prevention. Through its filings, STERIS discloses financial results, governance decisions, executive transitions and shareholder meeting outcomes, giving investors a structured view of the company’s regulatory history.
Current reports on Form 8-K filed by STERIS include items on Results of Operations and Financial Condition, where the company furnishes press releases announcing quarterly financial results. These filings reference segment performance for Healthcare, Applied Sterilization Technologies (AST) and Life Sciences, and describe the use of non-GAAP measures such as adjusted net income, adjusted earnings per diluted share, free cash flow, organic revenue growth and constant currency organic revenue growth.
Other 8-K filings address Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers, detailing transitions in the Chief Financial Officer role and related compensation and equity arrangements. Filings also summarize matters submitted to a vote of security holders, including the election of directors, appointment and remuneration of auditors, advisory votes on executive compensation and renewals of the Board’s authority to issue shares and opt out of statutory pre-emption rights under Irish law.
On this page, investors can review STERIS’s SEC reports alongside AI-powered summaries that explain the key points of each filing, highlight important sections and clarify technical language. Real-time updates from EDGAR ensure that new Forms 8-K and other reports appear promptly. Users can quickly identify filings related to quarterly earnings (such as 8-Ks furnishing press releases), governance and compensation topics, and other material events that shape STERIS’s financial and corporate profile.
STERIS plc reported stronger quarterly results for the three months ended September 30, 2025. Revenue rose to $1,460.3 million from $1,328.9 million as Healthcare delivered $1,033.8 million, Applied Sterilization Technologies $281.5 million, and Life Sciences $145.0 million. Operating income increased to $265.8 million from $219.7 million, with net income attributable to shareholders of $191.9 million (diluted EPS $1.94) versus $150.0 million ($1.51) a year ago. The effective tax rate was 23.9%.
Through six months, operating cash flow was $707.8 million, funding capital spending of $180.1 million and supporting cash balances of $319.2 million. Total debt declined to $1,897.3 million from $2,043.7 million. The company repurchased 0.4 million shares for $100.0 million and paid dividends of $1.20 per share year-to-date. Remaining performance obligations were $1,926.4 million, with approximately 53% expected to be recognized within one year.
STERIS plc furnished an 8-K to announce it issued a press release with financial results for the quarter ended September 30, 2025, which is its fiscal 2026 second quarter. The press release is attached as Exhibit 99.1.
The information under Item 2.02, including Exhibit 99.1, is being furnished to the SEC, not deemed “filed” under Section 18 of the Exchange Act, and is not incorporated by reference into Securities Act filings.
Massachusetts Financial Services Company filed an amended Schedule 13G reporting its beneficial ownership in STERIS plc (STE).
MFS reported beneficial ownership of 4,846,124 shares of STERIS common stock, representing 4.9% of the class as of the reported event date. The firm disclosed sole voting power over 4,674,537 shares and sole dispositive power over 4,846,124 shares, with no shared voting or shared dispositive power.
The filing certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of STERIS.
Director and CEO Daniel A. Carestio reported a small open-market sale of 159 ordinary shares on
STERIS plc filed a Form 144 reporting a proposed sale of 159 ordinary shares through Charles Schwab & Co., Inc. on
John Adam Zangerle, Senior Vice President, General Counsel and Secretary of STERIS plc (STE), reported that 202 restricted ordinary shares awarded on October 1, 2021 vested on October 1, 2025. Of those vested shares, 91 were withheld to satisfy tax withholding obligations, recorded as a disposition. After the transaction, Mr. Zangerle beneficially owns 33,669 ordinary shares. The filing notes 8,511 ordinary shares remain restricted with staggered lapse dates between June 1, 2026 and June 5, 2028. The Form 4 was signed by an authorized representative on October 3, 2025.
STERIS plc (STE) reported insider activity by its V.P. & Corporate Treasurer. On 10/01/2025, 26 ordinary shares were withheld (Code F) to cover taxes upon vesting of 86 restricted shares originally granted on 10/01/2021. Following the transaction, the reporting person beneficially owns 7,195 shares.
As of 10/01/2025, 1,475 of these shares are restricted, with scheduled lapses of restrictions as follows: 241 on 06/01/2026; 141 on 06/02/2026; 217 on 06/03/2026; 221 on 06/04/2026; 217 on 06/03/2027; 221 on 06/04/2027; and 217 on 06/05/2028.
STERIS plc (STE) reporting person Cary L. Majors, identified as SVP and President, Healthcare, reported transactions dated 10/01/2025. 692 ordinary shares vested that day from an award granted on 10/01/2021; 303 of those shares were withheld to satisfy required taxes, with a reported price of $0 for the withholding entry. After the transaction, the report shows 13,427 ordinary shares beneficially owned (direct) and 67 share equivalents held in the STERIS Corporation 401(k) Plan (indirect) as of 10/02/2025. The filing notes 10,138 ordinary shares remain restricted with scheduled lapses between 06/01/2026 and 06/05/2028. The form is signed by an authorized representative on 10/03/2025.
STERIS plc (STE) reported a Form 4 for its SVP & Chief HRO, reflecting tax withholding on vesting restricted shares. On October 1, 2025, 692 restricted ordinary shares vested, and 207 shares were withheld to cover taxes (Code F). Following the transaction, the officer beneficially owns 12,882 ordinary shares.
As of October 1, 2025, 8,886 of these shares are restricted, with restrictions scheduled to lapse as follows: 2,313 on June 1, 2026; 2,028 on June 2, 2026; 2,040 on June 4, 2027; and 2,505 on June 5, 2028.
Daniel A. Carestio, who serves as President and CEO and a Director of STERIS plc (STE), reported a Section 16 transaction dated 10/01/2025. On that date 289 restricted ordinary shares that had been awarded on 10/01/2021 vested and 130 of those vested shares were withheld to satisfy tax withholding obligations, leaving the reporting person with 51,255 ordinary shares beneficially owned following the transaction. The filing states that 33,054 ordinary shares remain restricted with scheduled lapse dates in June 2026, June 2027, and June 2028, and specifies the exact tranche amounts and dates for those restrictions.
FAQ
What is the current stock price of Steris Plc (STE)?
What is the market cap of Steris Plc (STE)?
